Member Info for doze

Lots of good news and dividend should eventually materialize. This was a write up on Shareprophets http://www.shareprophets.com/views/1170/entertainment-one-trading-update-shares-on-the-rise-but-further-to-go I bought in after Master investor at 186p so pleased with progress. Mark Slater tipped them from the stage. Thanks for your post here Chan.

"CMS's payment instructions for ODM usage set out clearly where CMS requires physicians to be paid for their use of ODM. Since the establishment of a procedure specific billing code for ODM in April, we have seen considerable interest from doctors aware of the decision and we look forward to its forthcoming wider dissemination." http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11664098

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11659771 sp up 6.33% today

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11657758 As at 5th March 2013, shareholders holding more than 3% of the share capital of Tissue Regenix Group Plc are: • Invesco Limited - 29.45% • Techtran Group Limited - 13.77% • ORA (Guernsey) Limited - 13.72% • The Northern Entrepreneurs Fund LLP - 4.67% • IP Venture Fund - 3.80% • University of Leeds - 5.21% • Henderson Global Investors - 3.21% • John Samuel – 3.66% • Alan Miller – 3.29% Shares not in public hands as at 5th March 2013 - 533,575,015 - 81.73% Shares in issue as at 5th March 2013 - 652,825,019 ordinary shares of 0.5p each

I think Deltex have the best product when compared to the competition but I suppose they would say that. I expect hospitals will make an informed/hands on choice.

http://www.4-traders.com/IOMART-GROUP-PLC-4002021/news/Iomart-Group-Plc-RapidSwitch-dedicated-hosting-supports-Xbox-gamers-social-network-boom-17123396/

Sorry about that rhjoyes. T B does some great research and can write it up in a very positive fashion. The latest I bought in to is DEMG, doing ok but IQE taking a tumble.

They sound very upright gents: a company we can trust to do their best to be a successs. from the website: Alan Buxton joined the Board of Gasol in February of 2012 from Standard Bank plc, where he was a Managing Director and Global Head of its Power and Infrastructure Group with responsibility for building the bank’s franchise in emerging markets, including Africa, and advising clients on domestic and cross border transactions. Prior to working with Standard Bank plc, he was a core member of Royal Bank of Canada’s Infrastructure Group from 2000 until 2008. He joined Royal Bank of Canada after three years at International Power plc where he led the development of new power projects, and the evaluation and acquisition of existing generating assets, in Europe, the Middle East and India. http://www.gasolplc.com/about-us/board-senior-management.aspx#

Just noticed this post which is positive I would say. Thanks Dutch, aswell.

Shame, tittle tattle sometimes gives a ceo the chance to say what he wants so am hoping something positive will emerge on the website.

http://www.lse.co.uk/ShareBrokerTips.asp?shareprice=TRX&share=tissue_regenix

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=TRX&ArticleCode=x4s3jo83&ArticleHeadline=Tissue_Regenix_advances_US_commercialisation Dr. David M. Smith, Chief Executive Officer of Community Tissue Services said: "We are extremely excited to partner with Tissue Regenix. Tissue Regenix's dCELL® Dermis will offer the latest technology in wound care management to patients suffering from acute and chronic wounds."

http://educate-yourself.org/nwo/ Is this the sort of thing you mean? or is it India Asia and Russia as a group you are alluding to or maybe even the US only which was at one time the New World. If you mean the middle option it would seem to be a good market to attack with least barriers.

reuters is good for the basics on the company. Still waiting but you didn't wait long for yesterdays rise. RHPS probably responsible http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=DEMG.L

http://www.heraldscotland.com/business/company-news/iomart-expands-into-virtual-desktops-line.21212770

http://www.heraldscotland.com/business/opinion/herald-view.21212790

http://www.londonstockexchange.com/companies-and-advisors/aim/advisers/rules/aim-rules-for-companies.pdf ♦ the number of AIM securities in issue (noting any held as treasury shares) and, insofar as it is aware, the percentage of AIM securities that is not in public hands together with the identity and percentage holdings of its significant shareholders. This information should be updated at least every 6 months. If he holds none, this will need updating at some stage http://www.iomart.com/investors/securities-information/shareholders

Thanks for the correction.

I am not equipped to differentiate PSA-EPO from Polytherics offering but on reading the website concluded it did a similar job. The scientific explanation on the XEN site does not impress me as much as the Polytheric offering. It is obviously a competitive corner of biopharma and Polytherics say they are hoping to licence just as Xen hope to. http://polytherics.com/index.php/about-us They are a private company so cannot invest in them. Xen have patented I know, but I would have thought there is not much difference in how these enablers work despite both firms having patented them. From the Polytherics website:" The technologies include reagents for the site-specific conjugation of therapeutic proteins, including a range of antibody formats, and peptides, a low viscosity polymer and a glycopolymer for targeted delivery." Just hope Scott pitches his licences at a competitive level, and steals a march, or we could lose out to competition.

That is not funny but neither is this share. I am a bit concerned that Polytherics communicate the biotech extremely well http://polytherics.com/index.php/working-with-us Wikepedia guff: Proteins consist of one or more polypeptides arranged in a biologically functional way, often bound to ligands such as coenzymes and cofactors, or to another protein or other macromolecule (DNA, RNA, etc.), or to complex macromolecular assemblies. Finally, while aspects of the techniques that apply to peptides versus polypeptides and proteins differ (i.e., in the specifics of electrophoresis, chromatography, etc.), the size boundaries that distinguish peptides from polypeptides and proteins are not hard and fast: long peptides such as amyloid beta have been referred to as proteins, and smaller proteins like insulin have been considered peptides. Xen obviously has a technology that will be applied but who will big pharma work with. polytherics seem to be a lower cost outfit and may have the march in brainpower. If they were a public company I would definitely invest with them. http://www.polytherics.com/index.php/applications/pkpd-optimisation